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Abstract 
Background: There is general international agreement that the importance of vivax malaria has been neglected, 
and there is a need for new treatment approaches in an effort to progress towards control and elimination in Latin 
America. This open label randomized clinical trial evaluated the efficacy and safety of three treatment regimens using 
either one of two fixed dose artemisinin-based combinations or chloroquine in combination with a short course of 
primaquine (7–9 days: total dose 3–4.2 mg/kg) in Brazil. The primary objective was establishing whether cure rates 
above 90% could be achieved in each arm.
Results: A total of 264 patients were followed up to day 63. The cure rate of all three treatment arms was greater than 
90% at 28 and 42 days. Cure rates were below 90% in all three treatment groups at day 63, although the 95% confi-
dence interval included 90% for all three treatments. Most of the adverse events were mild in all treatment arms. Only 
one of the three serious adverse events was related to the treatment and significant drops in haemoglobin were rare.
Conclusion: This study demonstrated the efficacy and safety of all three regimens that were tested with 42-day cure 
rates that meet World Health Organization criteria. The efficacy and safety of artemisinin-based combination therapy 
regimens in this population offers the opportunity to treat all species of malaria with the same regimen, simplifying pro-
tocols for malaria control programmes and potentially contributing to elimination of both vivax and falciparum malaria.
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Background
Malaria control and elimination activities have mainly 
focused upon Plasmodium falciparum as the leading 
cause of malaria mortality and morbidity worldwide. 
Nevertheless, Plasmodium vivax remains a major public 
health problem [1]. In 2010, 2.48 billion people world-
wide were living in areas at risk for vivax infection. Bra-
zil is the largest endemic area in the Americas; where 
stable transmission and a dispersed population [2, 3] 
pose major challenges for malaria control [4, 5]. In 2014, 
143,552 malaria cases were reported [6].
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Over the last 30 years, the proportion of malaria cases 
due to vivax in Brazil has increased from 50%, in 1988 
to 84% in 2014. Plasmodium vivax now causes 65% of 
hospitalizations due to malaria in the Brazilian Ama-
zon region, and 13 out of 38 malaria deaths in Brazil in 
2014 were due to P. vivax [6]. Control and management 
of this disease is therefore important, particularly in light 
of the increasing recognition that vivax infection is not 
as benign as first thought and that vivax can both cause 
severe disease [7–9], and have negative impacts on pros-
perity, longevity, school performance, pregnancy and the 
economy [10–12]. Optimizing the treatment of vivax 
malaria is critical to improve vivax control.
In Brazil, the current treatment recommended to treat 
vivax is chloroquine with concomitant use of 7 days of 
primaquine. The primaquine total dose ranges from 3 
to 4.2 mg/kg [13]. Recent trials have not demonstrated 
chloroquine resistant vivax in Brazil [14–16], although 
there are still concerns about chloroquine resistance 
emergence [17]. The availability of other options, par-
ticularly ones that may be useful for the treatment of 
both vivax and falciparum malaria, would help to avoid 
selective pressure over a single therapeutic regimen. 
This study was designed to evaluate new approaches 
for the acute treatment of vivax in preparation for 
plans for both vivax elimination and updated treatment 
guidelines.
This randomized clinical trial evaluated the efficacy and 
safety of three vivax treatment regimens using either an 
ACT or chloroquine with concomitant use of primaquine 
in Brazil. The primary objective was to establish whether 
cure rates above 90% could be achieved in each arm [18].
Methods
Study population
Patients with uncomplicated vivax malaria were included 
in the study, after giving informed consent, if they met the 
following inclusion criteria: age between 18 and 70 years; 
weight between 50 and 90  kg, P. vivax mono-infection 
confirmed by microscopy, asexual parasite count > 250/
μL, axillary temperature ≥  37.5  °C or a history of fever 
during the past 48 h, and haemoglobin > 7.0 g/dL. Exclu-
sion criteria were: malaria treatment in the previous 
63 days; signs of severe malaria; concurrent other febrile 
conditions or chronic disease (such as severe cardiac, 
hepatic or renal disorders or HIV); the use of any medi-
cation known to interfere with anti-malarial pharmacoki-
netics; previous history of intolerance to any study drug; 
known glucose-6-phosphate deficiency; pregnancy con-
firmed by urinary human chorionic gonadotropin (hCG) 
testing; and breastfeeding.
Study design and drug administration procedures
This prospective, randomized, open label, three-arm 
efficacy study of uncomplicated vivax malaria was con-
ducted according to World Health Organization (WHO) 
methods for surveillance of anti-malarial drug efficacy 
[18] at two centres in the Amazon Region of Brazil: the 
Tropical Medicine Research Centre (CEPEM) in Ron-
dônia and Tropical Medicine Foundation Dr Heitor 
Vieira Dourado (FMT-HVD) in Manaus.
A 90% cure rate or greater is considered by the WHO 
to be sufficient evidence of efficacy to support the choice 
of a specific regimen by National Malaria Control Pro-
grammes in their treatment guidelines [18]. The sample 
size was calculated with an expected failure rate of 5%. 
88 patients were included in each study arm to achieve 
a precision of 5% and allowing for 20% loss to follow-up, 
leading to a total of 264 patients.
A randomization list using blocks of six and alloca-
tion rate 1:1:1 was generated by software (Etcetera, ver-
sion 2.72). Sequentially numbered (0–176 CEPEM and 
177–264 FMT) opaque sealed envelopes were provided 
to the local clinical coordinators and used to randomize 
patients. Differences in dosing schedules and the diffi-
culty of dummy blinding meant that neither patients nor 
healthcare workers were blinded, but microscopists were 
not aware of treatment allocation. The statistician was 
blind to the treatment allocation until the database had 
been locked.
Eligible patients were allocated to one of the follow-
ing three treatment groups: (a) chloroquine (CQ); (b) 
fixed dose combination of artesunate and mefloquine 
(ASMQ) and; (c) fixed dose combination of artemether 
and lumefantrine (AL). All three arms received the same 
primaquine regimen.
Group A received chloroquine (Farmanguinhos—
Fiocruz, Batch Numbers 12080940 and 14060467) 
600 mg on day 1, and 450 mg on days 2 and 3. This is the 
Brazilian Ministry of Health current recommendation for 
uncomplicated malaria vivax treatment [13].
Group B received two tablets daily for 3 days of a fixed 
dose combination of 100  mg  +  200  mg artesunate and 
mefloquine (ASMQ) tablets (Farmanguinhos—Fiocruz 
Batch Numbers 11100680 and 13040348) in a total of six 
tablets.
Group C received four tablets twice a day for 3 days of 
a fixed dose combination of 20 mg + 120 mg artemether 
and lumefantrine (AL) tablets  (Coartem®—Novartis, 
Batch Numbers F2618 and K30711) in a total of 24 AL 
tablets.
All groups also received two tablets of 15  mg pri-
maquine (Pq) (Farmanguinhos—Fiocruz, Batch numbers 
12010038 and 13030282) for 7, 8 or 9  days (accord-
ing to three weight ranges;  ≥  50–69; 70–79; 80–90  kg, 
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respectively), as recommended by National Malaria 
Control Programme treatment guidelines [13]. Patients 
received a total primaquine dose between 3.0 and 4.2 mg/
kg.
The first 3 days’ treatment were supervised for Group 
A and B. For Group C, only the first daily AL dose was 
directly observed. Patients in the AL arm were asked 
about their adherence to the previous second daily dose 
after the morning supervised dose. For all groups, the 
first dose was administered after diagnosis, and all sub-
sequent supervised doses were taken between 8 and 
10 a.m. If the patient vomited within 30 min after a dose, 
the same dose was administered again. At D7 follow-up 
visit, patients were inquired about their treatment adher-
ence to unsupervised primaquine on days 4 through 7. 
The use of other treatments was recorded at every visit.
Glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency screening was not performed: this is not routinely 
performed in Brazil and it is not required by the national 
treatment guidelines. At enrolment, patients were asked 
about adverse events during previous primaquine use.
Ethics statement
The clinical study protocol and informed consent form 
were reviewed and approved by the Ethics Committee 
at CEPEM (No. 31/11 CEP/CEPEM 0018.0.046.000-
11 CAAE—SISNEP and Plataforma Brasil No. 74869 
CEP/CEPEM No. 05462612.7.0000.0011 CAAE). In 
April 2014, an amendment (No. 644.709 CEP/CEPEM) 
approved the inclusion of the second study site FMT-
HVD, in Manaus. The Brazilian National Council on Eth-
ics in Research (CONEP), Ministry of Health, accredits 
the CEPEM Ethics Committee. The study is registered 
at the Brazilian Register of Clinical Trials (RBR-79s56  s 
U1111-1132-8050), a primary repository of WHO. The 
clinical study was conducted in accordance with the Hel-
sinki Declaration (Edinburgh, 2000), Good Clinical Prac-
tice [19, 20] and the Brazilian National Health Council 
(CNS) resolution 466/2011. During the study, monitoring 
visits were conducted to ensure GCP adherence. Written 
informed consent was obtained for every subject prior to 
enrolment. If the study subject was illiterate, an impartial 
third party witnessed the informed consent process. All 
subjects were informed of the nature and possible associ-
ated risks of the trial and that they were free to withdraw 
their consent to participate at any time. The investigators 
and study staff ensured confidentiality of all records.
Efficacy and safety evaluations
Patients were assessed on the day of enrolment and on 
days 1, 2, 3, 7, 14, 21, 28, 42 and 63 days after study inclu-
sion. The scheduled study procedures comprised a full 
history, physical examination, and urinalysis at enrolment 
and assessment for clinical signs and adverse events (AE) 
at every follow-up visit. Blood samples were collected for 
parasite counts at 0, 3, 7, 14, 21, 28, 42 and 63 days, and 
haemoglobin was measured at 0, 14, 28, 42 and 63 days. 
An additional blood smear was also collected whenever 
treatment failed. Data was double entered using an elec-
tronic clinical record form (OpenClinica Community, 
version 3.1.3.1). Analysis was performed using R (version 
3.2.5).
The primary efficacy endpoint was the proportion of 
the population with an adequate clinical and parasito-
logical response (ACPR) at 63 days. Early treatment fail-
ure or late treatment failure were classified in line with 
standard WHO methodology [18]. The primary analysis 
was per protocol (PP); an intention-to-treat (ITT) anal-
ysis was also performed. The PP population excluded 
any participant with a protocol violation. Patients who 
missed the 28 or 42-day visit, but who had an ACPR at 
the subsequent follow visit was considered as a success at 
the previous visit. In the ITT population, protocol viola-
tions or losses to follow-up were considered as parasito-
logical and clinical failure.
The secondary efficacy endpoints included the success 
rate at day 3 (72 h after first drug administration) as well 
as gametocyte clearance, fever clearance, and the cumu-
lative success rate at days 28, 42 and 63.
The cumulative success rate by day 63, i.e. the probabil-
ity of remaining parasite-free at day 63, was calculated 
using a Kaplan–Meier survival curve. Categorical vari-
ables were summarized using frequencies and percent-
ages, while for quantitative variables, means, standard 
deviations (SD) and maximum–minimum values were 
used. Parasite counts were presented using geometric 
means.
The study was not designed to compare outcomes 
between treatment arms. However, exploratory analyses 
were conducted to explore the impact of the treatment 
arm on the safety and efficacy outcomes. The proportions 
of categorical variables were compared using Pearson’s 
Chi squared test with Yates’ continuity correction at sig-
nificance level of 5%. Nonparametric tests of Wilcoxon 
and Kruskal–Wallis were used for continuous variables. 
Additionally, generalized linear models (binominal and 
Poisson distribution, respectively) were used to estimate 
the effect of predictors (baseline characteristics and the 
use of other medications) on treatment success at day 63 
and the numbers of AEs that were possibly, probably or 
highly probably related to the treatment.
A safety analysis was conducted in the ITT population 
describing frequency, causality, and severity of AEs in 
each treatment arm. AEs reports were subdivided into: 
serious AEs, AEs leading to treatment suspension, and 
AEs which were described as possibly, probably or highly 
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probably related. The mean haemoglobin results at base-
line and follow-up are also presented.
Patients were encouraged to seek unscheduled assess-
ments if any AE was suspected. All clinical or laboratory 
abnormalities were categorized as Grade I to IV accord-
ing to the Common Terminology Criteria for Adverse 
Events (CTCAE) of the National Cancer Institute [21]. 
Any suspected serious AE (standard definitions) was 
reported to the sponsor and the Ethical Review Commit-
tee. Recognized drug-related events were recorded as an 
AE, even if it could be related to malaria.
Parasitological densities were estimated using 
Giemsa-stained blood slides at a magnification of 
1000× using WHO recommended methods [18]. Two 
trained microscopists read slides independently. The 
final density was calculated as the mean of the two read-
ings. A third microscopist examined slides if the two 
readers disagreed over whether there were parasites 
present, the species, or the parasite density (more than 
50% difference). In such cases, the final density was con-
sidered as the average of the two closest counts. A slide 
was considered as negative only after examining 1000 
leucocytes in microscopic fields. Gametocyte presence 
was also recorded.
Results
Baseline characteristics of the study population
A total of 2475 malaria thick smear positive patients were 
screened for inclusion in the two trial sites (CEPEM and 
FMT-HVD) from August 2012 to February 2015. 264 
(10.7%) were randomized (1:1:1) to one of three different 
treatment arms: CQ + Pq; ASMQ + Pq and AL + Pq. The 
same number of patients was allocated to each arm. The 
main reasons for not including patients were unavailabil-
ity for follow-up (19.9%), parasitaemia lower than 250/
μL (15.5%) and malaria treatment within the past 63 days 
(15.2%). Figure 1 shows the CONSORT flow diagram, see 
Additional file 1 for reasons not to be included. Twenty-
three patients did not complete the study; there was no 
difference in the proportions that discontinued between 
the arms. Only one protocol deviation occurred: the 
inclusion of a patient with a mixed infection, confirmed 
by PCR. The baseline characteristics of the patients were 
similar among the treatment groups (Table  1), and the 
ITT and PP populations.
There were 495 reports of concomitant medication 
use in the study. Analgesic and antipyretic were most 
frequently used (287 reports); there was no difference in 
use between the three arms. Use of anti-ulcer and anti-
spasmodic drugs were more common in the AL arm; 
accounting for 40.5% (15/27) and 69.6% (16/23) of the 
patients that used these classes, respectively.
A table presenting the medication used (grouped by 
therapeutic class) in each study arm, and a figure illus-
trating the most commonly used medications used per 
study visit and treatment group are provided (see Addi-
tional file 2).
Treatment adherence was 100% for ASMQ and CQ, as 
the dose during the initial 3 days was supervised. Nine-
teen patients reported AL non-adherence to the sec-
ond daily dose: 16 patients reported one missing dose, 
2 patients reported two missing doses, and one patient 
missed doses on three occasions. However, only one 
patient with incomplete AL adherence presented a treat-
ment failure at day 63. Patients were asked about Pq 
adherence at D7 visit. Only five patients reported incom-
plete treatment; two in each ASMQ + Pq and CQ + Pq 
arms and one in the AL +  Pq arm. None of them pre-
sented treatment failure.
Efficacy evaluation
The primary objective was to demonstrate cure rate 
above 90% in each study arm. The cure rate was defined 
as the proportion of the population with an adequate 
clinical and parasitological response (ACPR) at day 63. 
Cure rates were below 90% in all three treatment groups 
at day 63 in the PP population, although the 95% CI did 
include 90% for all three drugs: 85% (95% CI [77–93%]) 
of the ASMQ group, 88% (95% CI [81–95%]) of the CQ 
group, and 84% (95% CI [76–92%]) of the AL group 
achieved an ACPR at day 63. The cure rate of all the three 
treatment arms was greater than 90% at 28 and 42 days in 
the PP population (Table 2).
Cure rates in the ITT analysis were slightly lower (see 
Additional file 3) predominantly reflecting the very con-
servative approach to missing data. Secondary efficacy 
endpoints included the success rate at day 3 (72  h after 
first drug administration) and the cumulative success rate 
at days 28, 42 and 63, calculated using a Kaplan–Meier 
survival curve. These results are summarized in Fig. 2.
Parasitological success rates at day 3 were 100% for 
all arms in both PP and ITT analyses, apart from the 
AL + Pq arm where two dropouts (one informed consent 
withdraw, and one lost to follow-up) meant that the ITT 
success rate at day 3 was 98% (95% CI [98–100]).
Fever clearance is an important surrogate for cure in 
malaria. Only one patient in the CQ + Pq arm and two in 
the AL + Pq arm had an axillary temperature higher than 
37.5 °C at day 3. Four fever episodes were reported after 
day 7. One patient had fever at day 63 and was consid-
ered as a treatment failure. The other three patients com-
pleted 63 days follow up without evidence of parasites on 
microscopy. All patients cleared gametocytes by day 3. 
The five patients that had gametocytes present on day 2 
had all been treated with CQ + Pq (Fig. 3).
Page 5 of 11Daher et al. Malar J  (2018) 17:45 
Safety results
Three serious adverse events (SAE) were reported. One 
patient in the CQ arm had treatment suspended because 
of haemolytic anaemia on day 3. Qualitative calorimet-
ric test confirmed glucose-6-phosphate dehydrogenase 
(G6PD) deficiency. Another in the AL arm had a rise 
Fig. 1 CONSORT flow diagram
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in alanine aminotransferase (ALT) detected on day 12 
after treatment. The third SAE reflected elective surgery 
and was not related to the trial. All patients recovered 
completely.
The safety analysis was conducted in the ITT popula-
tion. A total of 1593 adverse events were reported. 1379 
of them (86.5%) were classified as grade I and 208 events 
(13.1%) were classified as grade II. The distribution of 
adverse events by age and weight range, and treatment 
arm is shown in Table 3.
749 events (41.0%) were reported as possible, probable/
likely or highly probably related to the treatment drug; 
48.9% were grade I, 35.1% were grade II, none grade III 
and one SAE (grade IV). The distribution of all adverse 
events according with their intensity and causality are 
presented at Table  4. The AE distribution per causality 
and treatment group is shown in Additional file 4.
The distribution of all adverse events according with 
their intensity and causality per treatment group is pro-
vided (see Additional file 5).
All adverse events (1593) were grouped based on the 
main body system affected and treatment allocation (see 
Additional file  6). Non-specific complaints were most 
common (483), followed by gastrointestinal (450). As 
these symptoms could reflect the clinical illness or an AE, 
they were only considered as AE, if they were not pre-
sent before dosing or they got worse after treatment. This 
overlap with symptoms may have led to an over estima-
tion of AE. Tables listing all AE with a frequency higher 
than 3% per regimen allocation are provided (see Addi-
tional file 7).
The study treatment AE profile was very similar 
between study groups with the only category showing 
any difference being the occurrence of insomnia and 
abdominal pain (p < 0.04 and p < 0.03 respectively), using 
Pearson’s Chi squared test.
Changes in haemoglobin (Hb) were a secondary out-
come. There was a slight decrease in all groups at day 
14 followed by recovery (Fig.  4). The median difference 
in haemoglobin at day 14 (Hb at day 14 −  Hb at base-
line/Hb at baseline) [22] in ASMQ + Pq, AL + Pq, and 
CQ +  Pq were −  0.74 (95% CI −  1.13; −  0.36), −  0.49 
(95% CI −  0.87; −  0.09), and −  0.58 (95% CI −  0.91; 
−  0.24), respectively. These were not statistically dif-
ferent. A drop of more than 20% from baseline was 
observed in 6 patients in each of the arms, ASMQ + Pq 
and AL + Pq and in 3 CQ + Pq patients. No patient had 
a drop of more than 30% from baseline. The mean and 
range haemoglobin at day 0, 14, 28, 42, and 63 is shown 
in Additional file 8. Unfortunately, haemoglobin was not 
Table 1 Baseline characteristics
Absolute number and percentage (%) were used to present categorical 
variables. Quantitative data presented using means, standard deviations (SD), 
and ranges [min–max]. Parasitaemia presented using geometric mean
Baseline characteristics Treatment group
ASMQ + Pq CQ + Pq AL + Pq
N (%) 88 (33.3%) 88 (33.3%) 88 (33.3%)
Study site
 CEPEM 66 (75.0%) 66 (75.0%) 66 (75.0%)
 FMT-HVD 22 (25.0%) 22 (25.0%) 22 (25.0%)
Gender
 Female 32 (36.4%) 22 (25.0%) 24 (27.3%)
 Male 56 (63.6%) 66 (75.0%) 64 (72.7%)
Age (years)
 > 59 3 (3.4%) 4 (4.5%) 3 (3.4%)
 18–39 45 (51.1%) 34 (38.6%) 49 (55.7%)
 39–59 40 (45.4%) 50 (56.8%) 36 (40.9%)
Weight (kg)
 > 80 25 (28.4%) 22 (25.0%) 27 (30.7%)
 50–65 27 (30.7%) 21 (23.9%) 23 (26.1%)
 65–80 36 (40.9%) 45 (51.1%) 38 (43.2%)
Fever
 < 37.5 48 (54.5%) 54 (61.4%) 53 (60.2%)
 > 37.5 40 (45.4%) 34 (38.6%) 35 (39.8%)
Weight (kg) 71.59 (10.99)
[51–90]
72.7 (10.34)
[53–90]
72.53 (10.59)
[50–90]
Temperature 37.45 (1.38)
[34.7–40.5]
37.31 (1.21)
[35.0–39.9]
37.38 (1.22)
[35.2–40.6]
Parasitaemia 2145 (2516.4)
[258–13,340]
2155 (2908.5)
[285–17,680]
2444 (3974.6)
[270–20,080]
Age (years) 38.75 (10.9)
[19.5–65.8]
41.88 (10.5)
[19.7–64.9]
37.24 (11.8)
[18.4–64.3]
Table 2 Proportion of treatment success per treatment arm in PP population at day 28, 42 and 63
Visit day Study treatment
ASMQ + Pq CQ + Pq AL + Pq
% (n) 95% CI % (n) 95% CI % (n) 95% CI
D28 100 (85) – 100 (82) – 96 (84) 92–100
D42 98 (83) 95–100 93 (82) 87–99 94 (82) 89–99
D63 85 (79) 77–93 88 (81) 81–95 84 (81) 76–92
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measured between 48  h and day 14; the lack of a day 7 
measurement is a limitation of this study.
The effect of the study population’s baseline charac-
teristics and the use of concomitant medication on the 
frequency of AE in each treatment arm was assessed. In 
this generalized linear model (Poisson distribution), the 
dependent variable was the count of possible, probable/
likely or highly probable AE related to the study treat-
ments per person. Adverse events were less common 
in males (OR 0.78; 95% CI 0.60–0.99; p = 0.04), but use 
of antipyretic or antihypertensive was associated with 
high rates of adverse events (OR 1.64; 95% CI 1.29–2.10; 
p  <  0.01 and OR 1.55; 95% CI 0.92–2.44; p  =  0.07, 
respectively).
Exploratory analyses
This study was not powered to detect differences in cure 
rates between treatment regimens and no statistically sig-
nificant difference could be detected between the treat-
ment arms at any time point.
A generalized linear model (binominal distribu-
tion) was used to explore the influence of baseline vari-
ables and concomitant treatments upon failure at day 
63, using a significance level of 5%. There was a strong 
association between the use of antipyretic medications 
Fig. 2 Kaplan–Meier survival analysis of the three treatment arms
Fig. 3 Clearance of gametocytes
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and treatment failure (OR 3.2; 95% CI 1.3–8.3; p = 0.01). 
A trend towards an association between the use of anti-
ulcerative drugs and treatment success was also observed 
(OR 0.12; 95% CI 0.001–0.73; p = 0.06).
The effect of the treatment on the time to clearance of 
gametocytes was evaluated in the three arms. Patients in 
the ASMQ + Pq and AL + Pq arm had all cleared game-
tocytes by day 2. In the CQ + Pq arm, 5 out of 43 patients 
(11.6%) had gametocytes present of day 2. Gametocytes 
only reappeared in five of the 103 patients, making mean-
ingful conclusions impossible.
Discussion
There has been recent international agreement that 
the importance of vivax malaria has been neglected 
[11, 23, 24], and that there is a need for new treatment 
approaches [25]. For most of the world, the first-line 
treatment recommendation of CQ + Pq has not changed 
since the 50s [11], despite the concerns about the emer-
gence of CQ-resistance [17]. Standard treatment has 
been based upon the need to clear both the red cell forms 
and the hepatic forms and the relatively slow emergence 
of resistance of P. vivax to chloroquine may be due to 
the fact that standard CQ +  Pq treatment has been an 
effective combination therapy [1]. In addition to clearing 
Table 3 Adverse events by  age, weight range, and  treat-
ment arm
Treatment group
n (%)
ASMQ + Pq CQ + Pq AL + Pq
Age (years)
 > 59 14 (30.4) 21 (45.7) 11 (23.9)
 18–39 190 (25.4) 255 (34.0) 304 (40.6)
 39–59 199 (24.9) 367 (46.0) 232 (29.1)
Weight (kg)
 50–70 131 (20.2) 238 (36.8) 278 (43.0)
 70–80 118 (25.8) 214 (46.7) 126 (27.5)
 80–90 154 (31.6) 191 (39.1) 143 (29.3)
Table 4 Distribution of all adverse events (1593) by intensity and causality
Italic values indicate the relevant safety outcomes
Grade Causality
n (%)
Total
Doubtful Unlikely Possible Probable/likely Highly probable
I 597 (37.5) 107 (6.7) 538 (33.8) 118 (7.4) 19 (1.2) 1379 (86.6)
II 86 (5.4) 49 (3.1) 62 (3.9) 10 (0.6) 1 (0.1) 208 (13.1)
IV 0 (0) 0 (0) 0 (0) 1 (0.1) 0 (0) 1 (0.1)
NA 3 (0.19) 2 (0.13) 0 (0) 0 (0) 0 (0) 5 (0.31)
Total 686 (43.1) 158 (9.9) 600 (37.7) 129 (8.1) 20 (1.3) 1593 (100)
Fig. 4 Haemoglobin per regimen allocation at day 0, 14, 28, 42, and 63
Page 9 of 11Daher et al. Malar J  (2018) 17:45 
hypnozoites, primaquine is active against blood stages of 
vivax [26] and chloroquine use also increases primaquine 
blood levels [27]; concomitant use of chloroquine and 
primaquine is more effective than sequential use [28].
ACT has been recommended by the WHO to treat 
vivax since 2010 [29], as it appears to have equivalent P. 
vivax schizonticidal activity to chloroquine [30] and it is 
recommended as the first-line treatment in areas of CQ-
resistant P. vivax emerges. There are compelling argu-
ments to look for a simpler and unified ACT treatment 
for both species of malaria. A single radical treatment 
would be useful in co-endemic areas where species 
diagnosis is difficult [31] or mixed infections occur that 
are misdiagnosed as P. falciparum. The use of ACT and 
primaquine for the treatment of P. falciparum infec-
tion also has the advantage of eradicating hypnozoites 
and preventing relapses from previous P. vivax infection 
that can happen following a P. falciparum infection [32]. 
There are also considerable logistic advantages for the 
use of ACT to treat both falciparum and vivax malaria 
with efficiencies of stock and supply management 
and an incentive to maintain ACT production as the 
requirement for falciparum treatment courses reduces.
In this study, all three treatment arms demonstrated 
cure rates > 90% in all treatment arms at day 42 but by 
day 63, cure rates had dropped below 90% (although all 
the 95% CI includes the 90% cure rate). It demonstrates 
the importance of a longer follow-up time in detecting 
failures, particularly in vivax when reinfection or relapse 
can occur [33]. This study did not detect any advantage 
from the use of an ACT with a longer half-life partner 
drugs, as has been shown previously; this may be due 
to the concomitant use of primaquine in our study [34]. 
Further studies with PCR analysis in an attempt to dis-
criminate reinfection from relapse would be of interest.
Drug interactions and the safety profile are important 
factors in choosing the optimum first line treatment, in 
addition to pill burden and food restrictions. This trial 
evaluated the efficacy and safety of three vivax treat-
ment regimens, and provides additional reassurance 
about the safety of ASMQ and AL when given with pri-
maquine; information that is considered important by 
WHO as strategies for control and elimination of P. vivax 
malaria are developed [1]. Most of the AE with ACT regi-
mens were mild to moderate (CTCAE grade I or II), and 
required minimal intervention. The frequencies of possi-
bly, probably/likely or highly probably related AE did not 
substantially vary between the CQ + Pq regimen and the 
ACT + Pq regimens.
Despite this low level of adverse events, the ACT and 
primaquine combination still has significant drawbacks. 
Its use is limited in pregnancy, breastfeeding and G6DP-
deficient population. The one SAE in this study was 
related to G6PD deficiency. These restrictions impose 
serious limitations to its use as an elimination tool in 
many parts of the world, although the primaquine regi-
men used in this study is the 7-day regimen currently 
recommended by the Brazilian National Malaria Control 
Programme. This regimen delivers a total dose from 3 
to 4.2 mg/kg [13]. This is the WHO recommended total 
dose (although suggested over 14 days) and this regimen 
retains efficacy in some parts of the world [35–37]. The 
7 day regimen has been suggested to improve adherence 
[13], although this has never been clearly demonstrated.
This study was not sufficiently powered to detect dif-
ferences between the three arms and only followed up 
patients for 63 days, meaning that late relapses would not 
have been detected. The study population did not include 
children, limiting the conclusions of efficacy in this pop-
ulations. The absence of PCR also meant that relapses 
could not be distinguished from reinfection; a critical 
issue in assessing vivax treatment. Nevertheless, this 
study demonstrates the efficacy and safety of two ACT 
and CQ in combination with 7  days of primaquine to 
treat uncomplicated vivax malaria in Brazil and demon-
strated the feasibility and utility of a standardized treat-
ment approach for all malaria cases.
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